Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Cash & Current Investments: 2019-2025

Historic Cash & Current Investments for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $2.0 million.

  • Pharming Group N.V's Cash & Current Investments rose 30.17% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 28.83%. This contributed to the annual value of $1.5 million for FY2024, which is 1.51% down from last year.
  • Pharming Group N.V's Cash & Current Investments amounted to $2.0 million in Q3 2025, which was down 26.08% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Cash & Current Investments ranged from a high of $206.3 million in Q1 2021 and a low of $225,324 during Q3 2021.
  • In the last 3 years, Pharming Group N.V's Cash & Current Investments had a median value of $1.5 million in 2023 and averaged $11.1 million.
  • As far as peak fluctuations go, Pharming Group N.V's Cash & Current Investments slumped by 99.88% in 2021, and later soared by 279.57% in 2023.
  • Over the past 5 years, Pharming Group N.V's Cash & Current Investments (Quarterly) stood at $1.0 million in 2021, then climbed by 9.28% to $1.1 million in 2022, then surged by 39.04% to $1.5 million in 2023, then decreased by 1.51% to $1.5 million in 2024, then surged by 30.17% to $2.0 million in 2025.
  • Its Cash & Current Investments was $2.0 million in Q3 2025, compared to $2.7 million in Q2 2025 and $1.6 million in Q1 2025.